Hosted on MSN1mon
FDA grants ODD to Tempest’s hepatocellular carcinoma treatment
The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist ...
Cure Today3d
The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma
The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or ...
GlobalData on MSN15d
FDA grants orphan drug status to Arbor Biotechnologies’ PH1
The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
Psychology Today2y
Oppositional Defiance (ODD) Therapists in New Jersey
Call now for a free 15-minute consultation 609-971-8989. The treatment of Oppositional defiant disorder (ODD) will involve multiple approaches designed to help both the youngster and their parents ...
Psychology Today1y
Oppositional Defiance (ODD) Therapists in Massachusetts
I rely on Exposure and Response Prevention as the gold standard treatment for OCD. Typical diagnoses include ADHD or ADD, anxiety, autism, and Oppositional Defiant Disorder. I am a behavior ...
PharmaTimes15d
FDA grants Orphan Drug Designation to Ariceum cancer therapy
Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its proprietary ...
PipelineReview.com1d
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of Peluntamig (PT217) in Combination with Chemotherapy
SAN DIEGO, CA, USA I February 19, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...
News Medical on MSN11d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
PharmiWeb9d
Lundbeck’s potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA
The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...